BibTex RIS Cite

Matrix metalloproteinases and lung cancer

Year 2006, Volume: 21 Issue: 2, 53 - 56, 01.03.2006

Hilal Oğuz Soydinç Hakan Çamlıca Derya Duranyıldız Esra Kaytan Sağlam Faruk Taş Vildan Yasasever Nejat Dalay

Abstract

OBJECTIVES The aim of this study was to determine the pretreatment levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in lung cancer patients. METHODS We investigated the serum MMP-9 and TIMP-1 values in 20 lung cancer patients by ELISA and the results were compared with the controls (n=20). RESULTS MMP-9 (p

Keywords

Lung Neoplasms Matrix Metalloproteinase 9 Tissue Inhibitor of Metalloproteinase-1 Enzyme-Linked Immunosorbent Assay

References

  • 1. Topuz E, Ayd›ner A. Akci¤er kanseri. In: Topuz E, Ayd›ner A, Karadeniz AN, editors. Klinik onkoloji. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 2000. p. 82-9.
  • 2. American Joint Commitee on Cancer (AJCC) Cancer staging manual. 5th ed. Philadelphia: LippincortRaven; 1997. p. 127-37.
  • 3. Darendeliler E. Akci¤er kanserinde radyoterapi. In: Topuz E, editör. Akci¤er kanseri. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 1995. p. 91-102.
  • 4. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002;3(4):409-21.
  • 5. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A 1990;87(1):364-8.
  • 6. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13(10):1550-7.
  • 7. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354(1-2):91-9.
  • 8. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52(16):4548-9.
  • 9. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Cancer Res 1999;5(1):149-53.
  • 10. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):1161-9.
  • 11. Pinto CA, Carvalho PE, Antonangelo L, Garippo A, Da Silva AG, Soares F, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 2003;9(8):3098-104.
  • 12. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer- -TIMP-1 as a prognostic marker. Anticancer Res 2000;20(2B):1311-6.
  • 13.Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004;98(2):173-7.
  • 14. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006;51(3):313-21.
  • 15. Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC. Expression of AKT2, Cyclin D1, and MMP-9 and Their Correlations to Clinicopathologic Features of Non-small Cell Lung Cancer. [Article in Chinese] Ai Zheng 2006;25(1):69-72. [Abstract]

Matriks metalloproteinazlar ve akciğer kanseri

Year 2006, Volume: 21 Issue: 2, 53 - 56, 01.03.2006

Hilal Oğuz Soydinç Hakan Çamlıca Derya Duranyıldız Esra Kaytan Sağlam Faruk Taş Vildan Yasasever Nejat Dalay

Abstract

AMAÇ Bu çalışmada akciğer kanserli hastalarda matriks metalloproteinaz- 9 (MMP-9) ve doku matriks metalloproteinaz inhibitörü- 1'in (TIMP-1) tedavi öncesi düzeylerinin belirlenmesi amaçlandı. GEREÇ VE YÖNTEM Çalışmamızda cerrahi ve radyoterapi uygulanmamış 20 akciğer kanserli hastada MMP-9 ve TIMP-1 değerleri ELISA yöntemi ile belirlendi ve sağlıklı kontrol grubu ile karşılaştırıldı (n=20). BULGULAR Hastaların MMP-9 (p

Keywords

Jelatinaz B akciğer kanseri akciğer/metabolizma/radyasyon etkileri akciğer neoplazisi/kan/enzimoloji/radyoterapi Matriks Metalloproteinaz MMP 9 doku matriks metalloproteinaz inhibitörü-1.

References

  • 1. Topuz E, Ayd›ner A. Akci¤er kanseri. In: Topuz E, Ayd›ner A, Karadeniz AN, editors. Klinik onkoloji. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 2000. p. 82-9.
  • 2. American Joint Commitee on Cancer (AJCC) Cancer staging manual. 5th ed. Philadelphia: LippincortRaven; 1997. p. 127-37.
  • 3. Darendeliler E. Akci¤er kanserinde radyoterapi. In: Topuz E, editör. Akci¤er kanseri. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 1995. p. 91-102.
  • 4. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002;3(4):409-21.
  • 5. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A 1990;87(1):364-8.
  • 6. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13(10):1550-7.
  • 7. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354(1-2):91-9.
  • 8. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52(16):4548-9.
  • 9. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Cancer Res 1999;5(1):149-53.
  • 10. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):1161-9.
  • 11. Pinto CA, Carvalho PE, Antonangelo L, Garippo A, Da Silva AG, Soares F, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 2003;9(8):3098-104.
  • 12. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer- -TIMP-1 as a prognostic marker. Anticancer Res 2000;20(2B):1311-6.
  • 13.Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004;98(2):173-7.
  • 14. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006;51(3):313-21.
  • 15. Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC. Expression of AKT2, Cyclin D1, and MMP-9 and Their Correlations to Clinicopathologic Features of Non-small Cell Lung Cancer. [Article in Chinese] Ai Zheng 2006;25(1):69-72. [Abstract]
There are 15 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Hilal Oğuz Soydinç This is me

Hakan Çamlıca This is me

Derya Duranyıldız This is me

Esra Kaytan Sağlam This is me

Faruk Taş This is me

Vildan Yasasever This is me

Nejat Dalay This is me

Publication Date March 1, 2006
Published in Issue Year 2006 Volume: 21 Issue: 2

Cite

APA Soydinç, H. O., Çamlıca, H., Duranyıldız, D., Sağlam, E. K., et al. (2006). Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi, 21(2), 53-56.
AMA Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N. Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi. March 2006;21(2):53-56.
Chicago Soydinç, Hilal Oğuz, Hakan Çamlıca, Derya Duranyıldız, Esra Kaytan Sağlam, Faruk Taş, Vildan Yasasever, and Nejat Dalay. “Matriks Metalloproteinazlar Ve akciğer Kanseri”. Türk Onkoloji Dergisi 21, no. 2 (March 2006): 53-56.
EndNote Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N (March 1, 2006) Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi 21 2 53–56.
IEEE H. O. Soydinç, H. Çamlıca, D. Duranyıldız, E. K. Sağlam, F. Taş, V. Yasasever, and N. Dalay, “Matriks metalloproteinazlar ve akciğer kanseri”, Türk Onkoloji Dergisi, vol. 21, no. 2, pp. 53–56, 2006.
ISNAD Soydinç, Hilal Oğuz et al. “Matriks Metalloproteinazlar Ve akciğer Kanseri”. Türk Onkoloji Dergisi 21/2 (March 2006), 53-56.
JAMA Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N. Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi. 2006;21:53–56.
MLA Soydinç, Hilal Oğuz et al. “Matriks Metalloproteinazlar Ve akciğer Kanseri”. Türk Onkoloji Dergisi, vol. 21, no. 2, 2006, pp. 53-56.
Vancouver Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N. Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi. 2006;21(2):53-6.